Gilead’s twice-yearly shot to prevent HIV succeeds in late-stage trial
June 20, 2024 at 11:22 AM EDT
Gilead's experimental twice-yearly medicine to prevent HIV was 100% effective in a late-stage trial, the company said Thursday.
|
||||||||||||
|
||||||||||||
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map |